Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration

a monoclonal antibody and western nile virus technology, applied in the field of bifunctional antibodies, can solve the problems of limited efficacy of peripheral delivery of this antibody in rodents, lack of effective and specific antiviral treatment of infection by wnv or other, and limited efficacy of the ultimate application as beneficial therapeutics

Active Publication Date: 2016-11-22
ARIZONA STATE UNIVERSITY
View PDF7 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Historically, there has been a lack of effective and specific antiviral treatment for infection by WNV or other flaviviruses (reviewed in 8).
Nonetheless, detailed studies show that while the E16 is therapeutically effective, peripheral delivery of this antibody has a limited window of efficacy in rodents.
Thus, even though antibodies have been identified as potential prophylactic and or therapeutic medicaments for WNV or other infectious diseases, their ultimate application as beneficial therapeutics is limited lack of efficacy due to the short therapeutic window.
Moreover, if biological drugs are too costly to produce for resource poor health care systems and cannot be easily made into generics, their therapeutic potential may never be realized.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
  • Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
  • Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods for Production of Hu-E16

[0067]Construction of pHu-E16 MAb Expression Vectors. The coding sequences of Hu-E16 MAb LC and HC (12) were optimized in silico with N. benthamiana-optimized codons using an algorithm described in (26). An 18-bp sequence coding for a ‘SEKDEL’ hexapeptide (SEQ ID NO: 13) ER-retention signal was added to the C-terminus of the HC gene. Optimized LC and HC sequences were synthesized (DNA 2.0) and cloned into the 5′ modules of plant expression vectors pICH21595 and pICH11599 of the MagnICON system as described previously (22).

[0068]Agroinfiltration of N. benthamiana. Plant expression vectors were individually transformed into Agrobacterium tumefaciens GV3101 by electroporation as previously described (45). Wild-type N. benthamiana plants were grown in a greenhouse with 16 / 8 hr light / dark cycle at 25° C. for 5 weeks. Plant leaves were co-Agroinfiltrated with GV3101 strains containing the LC and HC 5′ modules along with their respective 3′ mod...

example 2

Expression and Assembly of Hu-E16 MAb in Plants

[0081]As a first test of the feasibility of developing a plant-derived Hu-E16 therapeutic, we needed to demonstrate that plants could express and assemble Hu-E16. To ensure high-level expression of Hu-E16 in plants, the coding sequences of Hu-E16 light chain (LC) and heavy chain (HC) were optimized in silico with N. benthamiana-optimized codons (26). Optimized LC and HC sequences were cloned into the 5′ modules of plant expression vectors of the MagnICON system (22) and transformed into Agrobacterium tumefacient. To co-express Hu-E16 LC and HC, A. tumefacient strains harboring the LC and HC 5′ modules were co-delivered into N. benthamiana leaves along with their respective 3′ modules and an integrase construct through vacuum infiltration (22). Western blot analysis confirmed that the LC and HC of pHu-E16 were produced in leaves with the expected molecular weights of 25 kDa and 50 kDa, respectively (FIGS. 1A and B). Western blot analysis...

example 3

Purification and Scale-Up Production of pHu-E16

[0082]For plant-produced pHu-E16 to become a viable WNV therapeutic candidate, an efficient purification scheme from plant tissue must be developed. pHu-E16 was extracted and purified by a three-step purification protocol comprised of ammonium sulfate precipitation, protein A affinity and DEAE-anion exchange chromatographies. Precipitation with 35% ammonium sulfate effectively removed the most abundant plant host protein, the photosynthetic enzyme RuBisCo, and other plant proteins (FIG. 2B, Lane 2). Protein A affinity chromatography removed the remaining contaminating proteins and enriched pHu-E16 to greater than 95% purity (FIG. 2B, Lane 5). In the presence of a reducing agent, purified pHu-E16 was detected as the HC and LC (migration at ˜50 and 25 kDa) in the same stoichiometric ratio as the Hu-E16 produced in mammalian cells (FIG. 2B, Lanes 5 and 6). Under oxidizing conditions, purified pHu-E16 antibody assembled in its tetrameric fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
v/vaaaaaaaaaa
pHaaaaaaaaaa
flow rateaaaaaaaaaa
Login to view more

Abstract

The plant-based production of a therapeutic antibody against West Nile Virus is disclosed.

Description

RELATED APPLICATION[0001]This application claims priority under 35 U.S.C 119(e) to provisional U.S. Ser. No. 61 / 494,612 filed Jun. 8, 2011, which application is incorporated hereby by reference,FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with government support under U01 AI075549 awarded by NIH-NIAID. The Government has certain rights in the invention.SEQUENCE LISTING[0003]The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 27, 2012, is named 175551 WO.txt and is 451,050 bytes in size.FIELD OF THE INVENTION[0004]The present invention relates to a bifunctional antibody that has improved blood-brain barrier penetration. In exemplary embodiments the antibodies are plant-, mammalian- or other eukaryotic cell-produced antibodies against West Nile Virus that have an improved efficacy and therapeutic window for crossing ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): C07K16/10C07K16/46C07K16/28C07K19/00A61K39/00
CPCC07K16/10C07K16/1081C07K16/2869C07K16/2881C07K16/46A61K2039/505C07K19/00C07K2317/13C07K2317/24C07K2317/31C07K2317/41C07K2317/622C07K2317/64C07K2317/66C07K2317/734C07K2317/76C07K2317/90C07K2317/92Y02A50/30
Inventor CHEN, QIANGLAI, HUAFANGHE, JUNYUN
Owner ARIZONA STATE UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap